Massimo Di Maio, Director of the Genitourinary cancer Unit at National Cancer Institute Foundation, shared on X:
“Have a look at our viewpoint about the eNRGy trial, testing zenocutuzumab’s efficacy in patients with advanced cancer with NRG1 fusion.
Anyone clicking on the link before May 31, 2025 will be free to read or download the article.”
“eNRGy: Making progress toward a future for NRG1 fusion-positive cancer.”
Authors: Lucia Anna Muscarella, Massimo Di Maio
